(Q33836637)

29 July 2017

1 reference

title

Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club (English)

1 reference

spontaneous bacterial peritonitis

29 July 2017

main subject

1 reference

Rimola A

1

1 reference

29 July 2017

García-Tsao G

2

1 reference

29 July 2017

Navasa M

3

1 reference

29 July 2017

Piddock LJ

4

1 reference

29 July 2017

Planas R

5

1 reference

29 July 2017

Bernard B

6

1 reference

29 July 2017

Inadomi JM

7

1 reference

29 July 2017

publication date

1 January 2000

1 reference

29 July 2017

published in

Journal of Hepatology

1 reference

29 July 2017

volume

32

1 reference

29 July 2017

issue

1

1 reference

29 July 2017

page(s)

142-153

1 reference

Management of adult patients with ascites caused by cirrhosis

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

A prospective study of bacterial infections in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Spontaneous bacterial peritonitis in cirrhosis: predictive factors of infection resolution and survival in patients treated with cefotaxime

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Spontaneous bacterial peritonitis in cirrhosis. Incidence, diagnosis, and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Culture-negative neutrocytic ascites: a variant of spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Analysis of clinical course and prognosis of culture-positive spontaneous bacterial peritonitis and neutrocytic ascites. Evidence of the same disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Improved method for bacteriological diagnosis of spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Analysis of ascitic fluid in cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Ascitic fluid pH in alcoholic cirrhosis: a reevaluation of its use in the diagnosis of spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

The diagnosis of bacterial peritonitis: comparison of pH, lactate concentration and leukocyte count

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

White count, pH and lactate in ascites in the diagnosis of spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Immediate diagnostic criteria for bacterial infection of ascitic fluid. Evaluation of ascitic fluid polymorphonuclear leukocyte count, pH, and lactate concentration, alone and in combination

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Is the acidity of ascitic fluid a reliable index in making the presumptive diagnosis of spontaneous bacterial peritonitis?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

pH of ascitic fluid: diagnostic and prognostic value in cirrhotic and noncirrhotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Ascitic fluid polymorphonuclear cell count and serum to ascites albumin gradient in the diagnosis of bacterial peritonitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Increase in ascites white blood cell and protein concentrations during diuresis in patients with chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Characteristics of ascitic fluid in the alcoholic cirrhotic

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Culture-negative neutrocytic ascites: a less severe variant of spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Monomicrobial nonneutrocytic bacterascites: a variant of spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Asymptomatic bacterascites: is it spontaneous bacterial peritonitis?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Prevalence and prognostic significance of bacterascites in cirrhosis with ascites

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Ascitic fluid analysis in the differentiation of spontaneous bacterial peritonitis from gastrointestinal tract perforation into ascitic fluid

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Clarification of risk factors for abdominal operations in patients with hepatic cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Utility of an algorithm in differentiating spontaneous from secondary bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Cefotaxime concentrations in ascites

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Ascitic fluid and serum cefotaxime and desacetyl cefotaxime levels in patients treated for bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Use of ceftriaxone in the treatment of bacterial infections in cirrhotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Randomized trial comparing ceftriaxone with cefonicid for treatment of spontaneous bacterial peritonitis in cirrhotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

A prospective randomized trial of ceftazidime versus netilmicin plus mezlocillin in the empirical therapy of presumed sepsis in cirrhotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Aztreonam vs. cefotaxime in the treatment of gram-negative spontaneous peritonitis in cirrhotic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Amoxicillin-clavulanic acid therapy of spontaneous bacterial peritonitis: a prospective study of twenty-seven cases in cirrhotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Amoxicillin-clavulanic acid versus cefotaxime in the therapy of bacterial infections in cirrhotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Polymorphonuclear cell count response and duration of antibiotic therapy in spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Renal impairment after spontaneous bacterial peritonitis in cirrhosis: Incidence, clinical course, predictive factors and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Oral, nonabsorbable antibiotics prevent infection in cirrhotics with gastrointestinal hemorrhage

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Frequency of infections in cirrhotic patients presenting with acute gastrointestinal haemorrhage

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Prognostic significance of bacterial infection in bleeding cirrhotic patients: A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

The effect of ciprofloxacin in the prevention of bacterial infection in patients with cirrhosis after upper gastrointestinal bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: Relevance of ascitic fluid protein concentration

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Selective intestinal decontamination prevents spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Antibiotic Prophylaxis for the Prevention of Bacterial Infections in Cirrhotic Patients with Ascites: A Meta-Analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Cost-analysis of prophylactic antibiotics in spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

An economic analysis of norfloxacin prophylaxis against spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

High-level quinolone resistance amongst clinical isolates of Escherichia coli and Klebsiella pneumoniae from Spain.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Fluoroquinolone use and fluoroquinolone resistance: is there an association?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Mechanisms of resistance to fluoroquinolones: state-of-the-art 1992-1994.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Trends in bacterial resistance to fluoroquinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Emergence of ciprofloxacin resistance in Escherichia coli isolates after widespread use of fluoroquinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Fluoroquinolone resistance: overuse of fluoroquinolones in human and veterinary medicine can breed resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Comparison of ciprofloxacin, ofloxacin and pefloxacin for the prevention of the bacterial infection in neutropenic patients with haematological malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Effect of quinolones on the human intestinal microflora

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Colonization and infection with fluoroquinolone-resistant Escherichia coli among cancer patients: clonal analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Effects of oral ciprofloxacin on aerobic gram-negative fecal flora in patients with cirrhosis: results of short- and long-term administration, with daily and weekly dosages

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Survival after a first episode of spontaneous bacterial peritonitis. Prognosis of potential candidates for orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

Spontaneous bacterial peritonitis: an indication for liver transplantation?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

An analysis of liver transplant experience from 37 transplant centers as reported to Medicare.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980201-9

7 January 2021

10.1016/S0168-8278(00)80201-9

Identifiers

DOI

1 reference

29 July 2017

1 reference